Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Steve Pakola leaves Thrombogenics for Amakem

This article was originally published in Scrip

Executive Summary

Dr Steve Pakola has taken the role of CMO at Amakem, having previously served as CMO of Thrombogenics, where he played a pivotal role in the development of the company's lead product, ocriplasmin, which is under review in Europe as a treatment for symptomatic vitreomacular adhesion and has been filed for priority review in the US. Dr Pakola has been replaced at Thrombogenics by Dr Aniz Girach, who joined the company a year and a half ago as global head of clinical ophthalmology and was previously vice-president of international clinical development of ophthalmology at Alcon.

You may also be interested in...

Almirall launches Constella in six European markets

Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.

Dermira raises $35m in series B

Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.

Clovis ups public offering to $240m

Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.

Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts